TIGIT is overexpressed in tumor-infiltrating lymphocytes (TILs) from various solid tumours, including melanoma, glioblastoma,, non-small cell lung cancer, and liver cancer [11–14] Furthermore, TIGIT is linked to poor clinical outcomes of cancer. This evidence concerns the gene TIGIT and non-small cell lung carcinoma.